Rapid and efficient transfer of the T cell aging marker CD57 from glioblastoma stem cells to CAR T cells
Open accessAbstract
Adoptive transfer of T cells expressing chimeric antigen receptors (CARs) holds great promise for cancer treatment. We recently developed CAR T cells targeting the prototypic cancer stem cell marker AC133 and showed that these CAR T cells killed AC133+ glioblastoma stem cells (GBM-SCs) in vitro and inhibited the growth of brain tumors initiated from GBM-SCs in xenograft mouse models in vivo . Upon coincubation with GBM-SCs, we observed strong upregulation of the T cell aging marker CD57, but other phenotypical or functional changes usually associated with terminal T cell differentiation could not immediately be detected. Here, we provide evidence suggesting that CD57 is rapidly and efficiently transferred from CD57+ GBM-SCs to preactivated T cells and that the transfer is greatly enhanced by specific CAR/ligand interaction. After separation from CD57+ tumor cells, CD57 epitope expression on T cells decreased only slowly over several days. We conclude that CD57 transfer from tumor cells to T cells may occur in patients with CD57+ tumors and that it may have to be considered in the interpretation of phenotyping results for tumor-infiltrating lymphocytes and perhaps also in the characterization of tumor-specific T cells from tumor or lymph node homogenates or peripheral blood mononuclear cells.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CD57, a T cell senescence marker, can quickly and efficiently transfer from glioblastoma stem cells to CAR-T cells, leading to their senescence.
“Gabriele et al. reported that CD57, a T cell senescence marker, can quickly and efficiently transfer from glioblastoma stem cells to CAR-T cells, leading to its senescence [124].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The basic principles of chimeric antigen receptor (CAR) design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,423 · cited 1× · see citing works
“Tumor-specific chimeric antigen receptors (CARs) are recombinant molecules consisting of an antibody moiety specific for a tumor cell surface antigen fused to intracellular signaling domains of the physiological T cell receptor (TCR) and of costimulatory receptors [1].”
BackgroundJohn, L. B., Devaud, C., Duong, C. P. M., Yong, C. S. M., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 699 · cited 1× · see citing works
“The functionality of CAR T cells may also be compromised by these factors [10,11].”
BackgroundAntibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 617 · see citing works
What is trogocytosis and what is its purpose?
Joly, E., & Hudrisier, D. (2003) · Nature Immunology · doi:10.1038/ni0903-815 · Cited by 543 · cited 1× · see citing works
“The aforementioned findings suggest that T cells might gain CD57 via trogocytosis [17,18], a process where membrane fragments are directly transferred between cells within a few minutes and are detectable on the recipient cells for a considerable period of time [19-21].”
BackgroundStrioga, M., Pasukoniene, V., & Characiejus, D. (2011) · Immunology · doi:10.1111/j.1365-2567.2011.03470.x · Cited by 505 · cited 2× · see citing works
“Truly terminally differentiated T cells lose their proliferative capacity and expression of the positive costimulatory molecules CD27 and CD28, which usually correlates with loss of telomerase activity and critical shortening of the telomeres; in addition, they upregulate the cytotoxic granule molecules granzyme B and…”
BackgroundAre senescence and exhaustion intertwined or unrelated processes that compromise immunity?
Akbar, A. N., & Henson, S. M. (2011) · Nature Reviews Immunology · doi:10.1038/nri2959 · Cited by 474 · cited 2× · see citing works
“, processes that are induced by repetitive chronic TCRmediated stimulation [7-9].”
BackgroundGrosse‐Gehling, P., Fargeas, C. A., Dittfeld, C., Garbe, Y., Alison, M. R., Corbeil, D., & Kunz‐Schughart, L. A. (2012) · The Journal of Pathology · doi:10.1002/path.4086 · Cited by 299 · cited 1× · see citing works
“We recently reported on CAR T cells recognizing the cancer stem cell (CSC) antigen AC133, an N-glycosylationdependent, stem cell-specific epitope of CD133, marking CSCs of many tumor entities including the highly malignant glioblastoma multiforme (GBM) [4,5].”
BackgroundDavis, D. M. (2007) · Nature reviews. Immunology · doi:10.1038/nri2020 · Cited by 288 · cited 1× · see citing works
“The aforementioned findings suggest that T cells might gain CD57 via trogocytosis [17,18], a process where membrane fragments are directly transferred between cells within a few minutes and are detectable on the recipient cells for a considerable period of time [19-21].”
BackgroundLeMaoult, J., Caumartin, J., Daouya, M., Favier, B., Rond, S. L., González, Á., & Carosella, E. D. (2006) · Blood · doi:10.1182/blood-2006-05-024547 · Cited by 266 · cited 1× · see citing works
“The aforementioned findings suggest that T cells might gain CD57 via trogocytosis [17,18], a process where membrane fragments are directly transferred between cells within a few minutes and are detectable on the recipient cells for a considerable period of time [19-21].”
BackgroundCD57+ T lymphocytes and functional immune deficiency
Focosi, D., Bestagno, M., Burrone, Ó. R., & Petrini, M. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0809566 · Cited by 253 · cited 1× · see citing works
“Upon coincubation of CAR T cells with patient-derived GBM-SCs, we consistently observed an upregulation of CD57 [6], a terminally sulfated carbohydrate epitope best known as a marker for terminally differentiated, end-stage T cells [12,13].”
BackgroundLineage relationship of effector and memory T cells
Restifo, N. P., & Gattinoni, L. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.09.003 · Cited by 230 · cited 1× · see citing works
“, processes that are induced by repetitive chronic TCRmediated stimulation [7-9].”
BackgroundHudrisier, D., Riond, J., Mazarguil, H., Gairin, J. E., & Joly, E. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.6.3645 · Cited by 221 · cited 1× · see citing works
“For conventional T cells, evidence of membrane protein transfer from antigen-presenting cells or tumor cells by trogocytosis facilitated by specific peptide-MHC/TCR interaction has already been reported [23].”
BackgroundImmune-suppressive properties of the tumor microenvironment
Becker, J. C., Andersen, M. H., Schrama, D., & Straten, P. T. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1434-6 · Cited by 205 · cited 1× · see citing works
“, processes that are induced by repetitive chronic TCRmediated stimulation [7-9].”
BackgroundZhu, X., Prasad, S., Gaedicke, S., Hettich, M., Firat, E., & Niedermann, G. (2014) · Oncotarget · doi:10.18632/oncotarget.2767 · Cited by 156 · cited 10× · see citing works
“com/oncoscience 477 Oncoscience However, we neither observed a loss of the proliferative capacity of CD57+ CAR T cells upon subsequent shortterm re-exposure to AC133+ target cells nor did we observe the downregulation of CD27 or CD28 [6].”
BackgroundMethodResultInfluentialSelf-citationNoninvasive positron emission tomography and fluorescence imaging of CD133 + tumor stem cells
Gaedicke, S., Braun, F., Prasad, S., Machein, M. R., Firat, E., Hettich, M., Gudihal, R., Zhu, X., Klingner, K., Schüler, J. B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314189111 · Cited by 98 · cited 5× · see citing works
“Not only was the percentage of CD57+ T cells higher when CAR T cells were incubated with NCH421k GBM-SCs compared to NT T cells (Figure 1A), but also the mean fluorescence intensity (MFI) was higher (Figure 1B).”
MethodInfluentialSelf-citationVanherberghen, B., Andersson, K., Carlin, L. M., Hoen, E. N. M. N., Williams, G. S., Höglund, P., & Davis, D. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406240101 · Cited by 97 · cited 1× · see citing works
“The aforementioned findings suggest that T cells might gain CD57 via trogocytosis [17,18], a process where membrane fragments are directly transferred between cells within a few minutes and are detectable on the recipient cells for a considerable period of time [19-21].”
BackgroundManual of Diagnostic Antibodies for Immunohistology
Suvarna (1999) · Histopathology · doi:10.1046/j.1365-2559.1999.0660a.x · Cited by 81 · see citing works
The evolving landscape of glioblastoma stem cells
Yan, K. K.-L., Yang, K., & Rich, J. N. (2013) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000032 · Cited by 77 · cited 1× · see citing works
“We recently reported on CAR T cells recognizing the cancer stem cell (CSC) antigen AC133, an N-glycosylationdependent, stem cell-specific epitope of CD133, marking CSCs of many tumor entities including the highly malignant glioblastoma multiforme (GBM) [4,5].”
BackgroundGershon, T. R., Oppenheimer, O., Chin, S., & Gerald, W. L. (2005) · Neoplasia · doi:10.1593/neo.04637 · Cited by 68 · cited 1× · see citing works
“Intercellular transfer of CD57 from tumor cells to T cells may have to be considered in the interpretation of phenotyping results for TILs from CD57+ tumor entities such as brain tumors [6,24-26] and neuroectodermal tumors (including neuroblastoma, Ewing’s sarcoma, and melanoma [15,16,27,28]), at least in case of in s…”
BackgroundManual of Diagnostic Antibodies for Immunohistology
Leong, A. S. ‐., Cooper, K., & Leong, F. J. W.-M. (1998) · Cited by 56 · see citing works
Bilzer, T., Stavrou, D., Dahme, E., Keiditsch, E., Bürrig, K., Anzil, A. P., & Wechsler, W. (1991) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf01600156 · Cited by 44 · cited 1× · see citing works
“Intercellular transfer of CD57 from tumor cells to T cells may have to be considered in the interpretation of phenotyping results for TILs from CD57+ tumor entities such as brain tumors [6,24-26] and neuroectodermal tumors (including neuroblastoma, Ewing’s sarcoma, and melanoma [15,16,27,28]), at least in case of in s…”
BackgroundEshhar, Z. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2532 · Cited by 43 · cited 1× · see citing works
“CAR T cells have shown extraordinarily high activity against CD19+ hematological malignancies [2,3], and great efforts are undertaken to develop CAR T cells for the treatment of other hematological malignancies and solid tumors.”
BackgroundBonaccorsi, I., Morandi, B., Antsiferova, O., Costa, G., Oliveri, D., Conte, R., Pezzino, G., Vermiglio, G., Anastasi, G., Navarra, G., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301039 · Cited by 40 · cited 1× · see citing works
“The aforementioned findings suggest that T cells might gain CD57 via trogocytosis [17,18], a process where membrane fragments are directly transferred between cells within a few minutes and are detectable on the recipient cells for a considerable period of time [19-21].”
BackgroundWahl, J., Bogatyreva, L., Boukamp, P., Rojewski, M., van Valen, F., Fiedler, J., Hipp, N., Debatin, K., & Beltinger, C. P. (2010) · International Journal of Cancer · doi:10.1002/ijc.25163 · Cited by 23 · cited 2× · see citing works
“Since CD57 has been found on neuroblastoma and Ewing sarcoma cells with aggressive CSC-like features [15,16], we investigated if CD57 was expressed by the GBM-SCs.”
BackgroundWu, R. C. H., Liu, S., Chacon, J. A., Wu, S., Li, Y., Sukhumalchandra, P., Murray, J. L., Molldrem, J. J., Hwu, P., Pircher, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2034 · Cited by 23 · cited 1× · see citing works
“[14] recently described a subpopulation of melanoma-specific CD8+ tumor-infiltrating lymphocytes (TILs) with hybrid phenotypic and functional properties of both an early effector-memory cell and a terminally differentiated effector cell co-expressing CD27, CD28, and CD57.”
BackgroundThies, A., Schachner, M., Berger, J., Moll, I., Schulze, H., Brunner, G., & Schumacher, U. (2004) · The Journal of Pathology · doi:10.1002/path.1595 · Cited by 21 · cited 1× · see citing works
“Intercellular transfer of CD57 from tumor cells to T cells may have to be considered in the interpretation of phenotyping results for TILs from CD57+ tumor entities such as brain tumors [6,24-26] and neuroectodermal tumors (including neuroblastoma, Ewing’s sarcoma, and melanoma [15,16,27,28]), at least in case of in s…”
BackgroundSchlitter, A.-M., Dorneburg, C., Barth, T. F. E., Wahl, J., Schulte, J. H., Brüderlein, S., Debatin, K., & Beltinger, C. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042025 · Cited by 16 · cited 2× · see citing works
“Since CD57 has been found on neuroblastoma and Ewing sarcoma cells with aggressive CSC-like features [15,16], we investigated if CD57 was expressed by the GBM-SCs.”
BackgroundHombach, A. A., & Abken, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00135 · Cited by 13 · see citing works
Qi, L., Huang, Y., Kogiso, M., Mao, H., Baxter, P. A., Su, J. M. F., Perlaky, L., Lau, C. C., Chintagumpala, M., & Li, X. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-1484 · Cited by 1 · cited 1× · see citing works
“Intercellular transfer of CD57 from tumor cells to T cells may have to be considered in the interpretation of phenotyping results for TILs from CD57+ tumor entities such as brain tumors [6,24-26] and neuroectodermal tumors (including neuroblastoma, Ewing’s sarcoma, and melanoma [15,16,27,28]), at least in case of in s…”
Background
Flagged first, then by citations
Cited by
Sorted by citations
Immunosenescence: a key player in cancer development
Lian, J., Yue, Y., Yu, W., & Zhang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00986-z · Cited by 510 · see citing works
Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness
Chen, J., Qiu, S., Li, W., Wang, K., Zhang, Y., Yang, H., Liu, B., Li, G., Li, L., Chen, M., et al. (2023) · Cell Research · doi:10.1038/s41422-023-00789-0 · Cited by 195 · see citing works
T cells from patients with Candida sepsis display a suppressive immunophenotype
Spec, A., Shindo, Y., Burnham, C. D., Wilson, S., Ablordeppey, E., Beiter, E. R., Chang, K. C., Drewry, A. M., & Hotchkiss, R. S. (2016) · Critical Care · doi:10.1186/s13054-016-1182-z · Cited by 131 · see citing works
“These molecules included CD69, an early activation marker, CD28, a key positive co-stimulatory molecule, IL-7 receptor (IL-7R), which is decreased in exhausted T cells, the negative co-stimulatory molecules T cell immunoglobulin domain and mucin domain 3 (TIM-3) and B and T lymphocyte attenuator (BTLA), and CD57 which…”
BackgroundDifferent T-cell subsets in glioblastoma multiforme and targeted immunotherapy
Wang, H., Zhou, H., Xu, J., Lu, Y., Ji, X., Yao, Y., Hou, C., Zhang, J., Zhang, X., Yao, S., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.028 · Cited by 87 · see citing works
Cellular senescence in cancer: molecular mechanisms and therapeutic targets
Jin, P., Duan, X., Li, L., Zhou, P., Zou, C., & Xie, K. (2024) · MedComm · doi:10.1002/mco2.542 · Cited by 46 · see citing works
Choi, B. D., Curry, W. T., Carter, B. S., & Maus, M. V. (2018) · Neurosurgical FOCUS · doi:10.3171/2018.2.focus17788 · Cited by 32 · see citing works
Stromal senescence contributes to age-related increases in cancer
Ye, J., Melam, A., & Stewart, S. A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00840-9 · Cited by 14 · see citing works
Tang, J., Zou, Y., Li, L., Lu, F., Xu, H., Ren, P., Bai, F., Niedermann, G., & Zhu, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.619800 · Cited by 12 · see citing works
Self-citationCheng, J., Zheng, J., Ma, C., Li, Y., & Hao, H. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.010 · Cited by 8 · see citing works
Multiple Dynamics in Tumor Microenvironment Under Radiotherapy
Huang, J., & Li, J. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-44518-8_10 · Cited by 8 · see citing works
The Biological Significance of Trogocytosis
Agbakwuru, D., & Wetzel, S. A. (2024) · Results and problems in cell differentiation · doi:10.1007/978-3-031-62036-2_5 · Cited by 6 · see citing works
Trogocytosis at crossroads: Navigating the duality in tumor-immune cell interactions
Yang, X. L., Huang, X., Chen, Z., Zhang, W., Liu, O., Wu, J., & Yan, F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189431 · Cited by 2 · see citing works
van den Broecke, L., der Vreken, A. V., Watté, F., Meeus, F., Veirman, K. D., Breckpot, K., Bruyne, E. D., & Menu, E. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02923-x · Cited by 3 · see citing works
Noncanonical intercellular communication in immune response
Kloc, M., Kubiak, J. Z., Li, X. C., & Ghobrial, R. M. (2016) · World Journal of Immunology · doi:10.5411/wji.v6.i1.67 · Cited by 2 · see citing works
Dual roles of immunosenescence in cancer immunotherapy
Yu, Y., Sun, L., & Fan, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1779141
- Authors
- Zhu, X., & Niedermann, G.
- Affiliations
- German Cancer Research Center (DE)
- Venue
- Oncoscience
- Publisher
- Impact Journals, LLC
- Published
- 2015-05-15
- Volume
- 2
- Issue
- 5
- Pages
- 476-482
- ISSN
- 2331-4737 (ISSN-L)
- PMC
- PMC4468333
- OpenAlex
- W2183458671
- Cited by
- 15
- References
- 29
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 1 · 2021: 1 · 2020: 3 · 2018: 1 · 2016: 2
- FWCI
- 0.44
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Oncoscience (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD57, T cell senescence, glioblastoma stem cells, chimeric antigen receptor T cells, CD133, adoptive T cell therapy, tumor-infiltrating lymphocytes, tumor-specific T cells, T cell differentiation, tumor antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
